Anti-pvrig protein antibodies or antibody fragments and uses thereof
By designing antibodies or antibody fragments with specific sequences, the shortcomings of existing PVRIG-targeting antibodies in blocking the binding of PVRIG to CD112 in cancer treatment have been overcome, achieving highly efficient tumor killing and immune system activation, and significantly inhibiting tumor growth.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HEFEI TG IMMUNOPHARMA CO LTD
- Filing Date
- 2021-03-08
- Publication Date
- 2026-05-19
AI Technical Summary
Existing PVRIG-targeting antibodies still need further improvement in cancer treatment to effectively block the binding of PVRIG to its ligand CD112 and enhance the killing effect of the immune system on tumor cells.
An antibody or antibody fragment is provided, comprising specific heavy and light chain complementarity-determining region (CDR) sequences, capable of binding PVRIG with high affinity and blocking the interaction between PVRIG and CD112, including heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, achieving efficient binding and blocking through specific amino acid sequence design.
This antibody or antibody fragment can specifically bind to PVRIG, significantly enhancing the killing effect on human PBMCs. It also exhibits significant anti-tumor effects in mouse models, promoting the cytotoxicity of NK cells and IFN-γ secretion, and inhibiting tumor growth.
Smart Images
Figure BDA0002965773080000281 
Figure BDA0002965773080000282 
Figure HDA0002965773090000011
Abstract
Claims
1. An anti-PVRIG antibody or antibody fragment, characterized in that, The antibody or antibody fragment includes heavy chain complementarity-determining regions HCDR1, HCDR2 and HCDR3, and light chain complementarity-determining regions LCDR1, LCDR2 and LCDR3. HCDR1 is the sequence shown in GYTFSSFS. HCDR2 is the sequence shown in ILPGSNST. HCDR3 is the sequence shown in SSYWFAY; Wherein, LCDR1 is the sequence shown in QSLLNSGNQKNY. LCDR2 is the sequence shown in GAS; LCDR3 is the sequence shown in QNAHSYPPT.
2. An anti-PVRIG antibody or antibody fragment, characterized in that, The antibody or antibody fragment is selected from at least one of the following: (1) The antibody or antibody fragment includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is the sequence shown in SEQ ID NO:1 and the light chain variable region is the sequence shown in SEQ ID NO:2; (2) The antibody or antibody fragment includes a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region is selected from the sequences shown in SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, and SEQ ID NO:33, and the light chain variable region is the sequence shown in SEQ ID NO:
36.
3. The antibody or antibody fragment according to claim 2, characterized in that, It includes a heavy chain and a light chain, wherein the amino acid sequence of the heavy chain is the sequence shown in SEQ ID NO:22, SEQ ID NO:25, SEQ ID NO:28, SEQ ID NO:31, and SEQ ID NO:34; The light chain amino acid sequence is the sequence shown in SEQ ID NO:
37.
4. A separable nucleic acid, characterized in that, The nucleic acid encodes the antibody or antibody fragment as described in any one of claims 1 to 3.
5. An expression carrier, characterized in that, The expression vector contains the nucleic acid as described in claim 4.
6. A host cell, characterized in that, The host cell expresses the antibody or antibody fragment as described in any one of claims 1 to 3.
7. The host cell according to claim 6, characterized in that, The host cell contains the expression vector as described in claim 5.
8. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises the antibody or antibody fragment of any one of claims 1 to 3 and a pharmaceutically acceptable carrier.
9. Use of the antibody or antibody fragment of any one of claims 1 to 3 or the pharmaceutical composition of claim 8 in the preparation of a medicament for treating cancer; The cancers mentioned are selected from squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, glial cell tumors, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, melanoma, colorectal cancer, endometrial cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, or thyroid cancer.
10. A pharmaceutical combination composition, characterized in that, include: (1) The antibody or antibody fragment of any one of claims 1 to 3, or the pharmaceutical composition of claim 8; and (2) Antibodies used for cancer treatment that are different from (1).